The prognostic value of long noncoding RNA SNHG16 on clinical outcomes in human cancers: a systematic review and meta-analysis

Table 3 Correlation between lncRNA SNHG16 expression and clinicopathologic parameters for cancers

Clinicopathologic parameters	No. of studies	No. of participants	Pooled OR (95% CI)	P	Model	Heterogeneity
Clinicopathologic parameters	No. of studies	No. of participants	Pooled OR (95% CI)	P	Model	Chi², P-value, I² (%)
Age (≥ 60/< 60)	5	391	1.06 (0.71, 1.58)	0.79	Fixed	0.38, 0.98, 0
Gender	4	288	1.06 (0.66, 1.70)	0.80	Fixed	2.26, 0.52, 0
Smoking history	3	240	1.03 (0.62, 1.71)	0.90	Fixed	1.94, 0.38, 0
Tumor size (≥ 5 cm/<5 cm)	2	84	6.36 (2.43, 16.60)	0.0002	Fixed	0.02, 0.88, 0
Clinical stage	2	194	2.91 (1.60, 5.28)	0.0005	Fixed	1.29, 0.26, 23
LNM	4	278	4.42 (2.66, 7.35)	< 0.00001	Fixed	5.51, 0.14, 46
DM	2	149	3.86 (1.92, 7.77)	0.0002	Fixed	0.84, 0.36, 0

CI confidence interval, DM distant metastasis, LNM lymph node metastasis, OR odds ratio, SNHG16 small nucleolar RNA host gene 16

ISSN: 1475-2867